- Open Access
Dopamine receptor repertoire of human granulosa cells
© Rey-Ares et al; licensee BioMed Central Ltd. 2007
- Received: 06 July 2007
- Accepted: 25 October 2007
- Published: 25 October 2007
High levels of dopamine (DA) were described in human ovary and recently evidence for DA receptors in granulosa and luteal cells has been provided, as well. However, neither the full repertoire of ovarian receptors for DA, nor their specific role, is established. Human granulosa cells (GCs) derived from women undergoing in vitro fertilization (IVF) are an adequate model for endocrine cells of the follicle and the corpus luteum and were therefore employed in an attempt to decipher their DA receptor repertoire and functionality.
Cells were obtained from patients undergoing IVF and examined using cDNA-array, RT-PCR, Western blotting and immunocytochemistry. In addition, calcium measurements (with FLUO-4) were employed. Expression of two DA receptors was also examined by in-situ hybridization in rat ovary. Effects of DA on cell viability and cell volume were studied by using an ATP assay and an electronic cell counter system.
We found members of the two DA receptor families (D1- and D2 -like) associated with different signaling pathways in human GCs, namely D1 (as expected) and D5 (both are Gs coupled and linked to cAMP increase) and D2, D4 (Gi/Gq coupled and linked to IP3/DAG). D3 was not found. The presence of the trophic hormone hCG (10 IU/ml) in the culture medium for several days did not alter mRNA (semiquantitative RT-PCR) or protein levels (immunocytochemistry/Western blotting) of D1,2,4,5 DA receptors. Expression of prototype receptors for the two families, D1 and D2, was furthermore shown in rat granulosa and luteal cells by in situ hybridization. Among the DA receptors found in human GCs, D2 expression was marked both at mRNA and protein levels and it was therefore further studied. Results of additional RT-PCR and Western blots showed two splice variants (D2L, D2S). Irrespective of these variants, D2 proved to be functional, as DA raised intracellular calcium levels. This calcium mobilizing effect of DA was observed in the absence of extracellular calcium and was abolished by a D2 blocker (L-741,626). DA treatment (48 h) of human GCs resulted in slightly, but significantly enlarged, viable cells.
A previous study showed D2 in human GCs, which are linked to cAMP, and the present study reveals the full spectrum of DA receptors present in these endocrine cells, which also includes D2-like receptors, linked to calcium. Ovarian DA can act thus via D1,2,4,5, which are co-expressed by endocrine cells of the follicle and the corpus luteum and are linked to different signaling pathways. This suggests a complex role of DA in the regulation of ovarian processes.
- Splice Variant
- Endocrine Cell
- Corpus Luteum
- Luteal Cell
- Human Ovary
High levels of the catecholamine dopamine (DA) were described in human ovary [1, 2], raising questions about its role in the female gonad. Several possibilities have so far been suggested. It has been reported that monkey (Macaca mulatta) oocytes are able to take up DA and use it as precursor for the synthesis of noradrenaline (NE) , with the help of dopamine-β-hydroxylase (DBH), expressed by oocytes. NE may then be able to interact with ovarian alpha- and beta-receptors present on granulosa cells (GCs) of the follicle [2, 4, 5]. Furthermore, bovine luteal cells are reported to perform synthesis of NE in a similar way  and presumably this occurs also in intraovarian nerve fibers and neuron-like cells [7–9], which likewise express DBH. Thus, ovarian DA can be viewed as a precursor for NE in oocytes, endocrine cells and nerve cells and may have a plethora of functions (for example, steroid production and induction of follicle-stimulating hormone receptors) [9–11].
Nevertheless, recent publications have hinted to a yet different function. DA can, in general, act via its five different receptor subtypes (D1-D5), which are organized in two families (D1-like/D2-like) and one of them, D1, has been described in human luteinizing GCs [12, 13] and more recently in endocrine cells of horse ovary . In human GCs, isolated from preovulatory follicles of women undergoing in vitro fertilization (IVF) procedures, activation of D1 by selective agonists, as well as treatment with DA itself, did not affect progesterone synthesis . D1 activation was rather associated with cAMP elevations and increased phosphorylation of DARPP-32 (DA and cAMP regulated phospho-protein of MR 32,000), which is a down-stream third messenger of DA, but also with other signaling molecules in ovary and other tissues [12, 13, 15–18].
Whether other receptors for DA are present in ovary and on GCs and may thus provide a basis for its action, has as yet not been thoroughly examined. However a recent description of D2 in horse granulosa and luteal cells  prompted us to examine whether this and other DA receptors are also present in rat and human ovary. For functional studies we focused on human GCs.
Human cells: GC preparation and culture
Human GCs were obtained from follicular aspirates of women undergoing IVF, as described [12, 13, 19–21]. They were separated by centrifugation at 560 × g for 3 min and subsequent washing in serum-free DMEM/Ham's F-12 medium (1:1, Sigma, Deisenhofen, Germany). Washed cells were resuspended in culture medium supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml), and 10% fetal calf serum as previously described . The use of the cells for scientific experiments had been approved by the ethic's committee of the University of Munich (LMU), and written consent of the patients was obtained. For Ca2+ imaging and immunocytochemistry experiments, cells were cultured on glass cover slips, otherwise in plastic dishes or well plates in a humidified atmosphere with 5% CO2 at 37°C. Cells were used for the experiments described either on day 3 or day 4 after isolation. One group of cells was cultured with basal medium, which for the other group was supplemented with hCG (Sigma, 10 IU/ml; from the 1st day of culture).
Cells cultivated for 3 days were harvested and total RNA was prepared as previously described [9, 13, 19, 20] using RNEasy kit (Qiagen, Hilden, Germany). A total of 5 ng was used for the GEArray Q Series Human Neuroscience-1 Ion Channel & Transporter Gene Array (SuperArray Bioscience Corporation, Biomol, Hamburg Germany), as described , following the instructions of the manufacturer. The array included D1, D2, D3, D5, but not D4, in quatriplicate spots. Negative controls consisted of puc18 plasmid cDNA. Chemiluminescence signals were recorded.
Total RNA from several batches of cultured GCs (3 and 4 days after isolation) was prepared using RNEasy kit (Qiagen). As previously described [12, 22], total RNA (200–500 ng) was subjected to reverse transcription, using random primers (pdN6) and Superscript-RT II (Life Technologies, Karlsruhe, Germany). Commercial human brain cDNA (BD CLONTECH, Inc., Heidelberg, Germany) was used in addition.
Informations about oligonucleotide primers used for PCR amplification: Sense, antisense and antisense nested primer sequences, as well as their positions in the published D1-D5 sequences are provided.
Human dopamine receptor D1
Genebank accession number/location of primer
5'-CTG AAG ACT CTG TCG GTG A-3'
5'-ACT CAC CGT CTC TAT GGC A-3'
5'TGT AGC ATC CTA AGA GGG T-3'
Human dopamine receptor D 2
5'-TTC TAC GTG CCC TTC AT-3'
5'-GGT CTG GAT CTC AAA GA-3'
nested D2 common
5'-GAG CAT CTC CAT CTC CA-3'
nested D2 long
5'- ACT GGG AAA CTC CCA TT-3'
Human dopamine receptor D 3
5'-GGT ACT GGC CTT TGC TGT GTC C-3'
5'-ATC CTT TTC CGT CTC CTT TGT TTC-3'
5'-CCA AAG GGC AGG TAG AAG GAC-3'
Human dopamine receptor D 4
5'-CCT TGC GGC TCC AAC TGT G-3'
5'-AGC GCC TGC GTG ATG TGC-3'
5'-GAA GGC CCC GAC CAC CAC-3'
Human dopamine receptor D 5
5'-GGG CAG TTC GCT CTA TAC CAG-3'
5'-CAG GAA AAG GTC TGA CAC GG-3'
5'-CAG AGA CAC GAT GAA GAC GTT-3'
In order to be able to evaluate at least semiquantitatively possible changes after treatment of the cultures with hCG, or to take into account small loading differences, in all samples cyclophilin was co-amplified, as described before .
The PCR reaction products were separated on 2% agarose gels and visualized with ethidium bromide. The identities of all PCR products were verified by direct sequencing using one of the specific primers .
Measurements of intracellular Ca2+ concentrations
Ca2+ measurements were performed on human GCs (day 3 or 4) cultured on glass cover slips, as described [21, 25]. Two groups of cells were examined, namely cells kept without or treated with hCG (10 IU/ml; since the 1st day of culture). Briefly, the medium was replaced by fresh serum-free DMEM/Ham's F-12 medium containing 5 μM fluo-4 AM (Molecular Probes, Eugene, OR, USA) and cells were loaded for 30 min at 37°C and 5% CO2. Finally, cells were washed in extracellular solution (140 mM NaCl, 3 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM HEPES and 10 mM glucose; pH 7.4) and were put into a recording chamber mounted on a TCS SP2 confocal microscope (Leica Microsystems, Bensheim, Germany). DA and carbachol (Sigma) were applied in 0.1 μM and 100 μM, respectively. The D2 selective antagonist used was L-741,626 (1 nM, Tocris Cookson Inc. Missouri, USA). Changes in fluorescence intensity were monitored for 10 min by sampling every 2 s at excitation and emission wavelengths of 488 nm and 520 ± 20 nm, respectively. The Ca2+ free experiments were done with extracellular solution without Ca2+ plus EGTA (2 mM).
The cellular distribution of D1,2,4,5 proteins in cultured GCs was determined by immunocytochemistry using commercially available polyclonal antisera (rabbit anti-D1 receptor, R&D, Berkeley, CA, AS-3512G, 1:500; rabbit anti-D2, BioTrend Chemikalien Gmbh, Köln, Germany, AS-3526S, 1:500; rabbit anti-D4; Chemicon International Inc., Temecula, CA, AB9422, 1:200; rabbit anti-D5, R&D, Berkeley, CA, AS 3552G, 1:200). GCs were fixed on slides (Zamboni's fixative) and used directly after rinsing in 10 mM PBS (pH 7.4). Incubation with the antiserum was carried out overnight in a humidified chamber. A fluorescein isothiocyanate-labeled secondary goat anti-rabbit antiserum was used. For control purposes, the first antiserum was omitted, and incubations with normal rabbit serum were carried out instead. Sections were examined with a Zeiss Axiovert microscope (Zeiss, Oberkochen, Germany), equipped with a fluorescein filter set.
Western blot analyses
Western blotting was performed as previously described [12, 13, 18]. In brief, GCs cultured with or without hCG (10 IU/ml for up to 4 days) were harvested, frozen, thawed, homogenized in 62.5 mM Tris-HCl buffer (pH 6.8) containing 10% sucrose and 2% SDS, sonicated, and heated (95°C for 5 min) in the presence of 10% mercaptoethanol. Samples (15 μg/lane) were separated electrophoretically on 10% or 12.5% SDS-polyacrylamide gels (SDS/PAGE). Proteins were transferred onto nitrocellulose membranes and probed with D1 and D2 antisera, as used for immunocytochemistry (1:1,000 dilution). Immunoreactivity was detected using peroxidase-labeled antisera (1:3,000, Dianova, Hamburg, Germany) and enhanced chemiluminescence, as described [12, 13, 18] (Amersham Buchler, Braunschweig, Germany). In some cases, the blots were digitized, and integrated optical densities of the bands were determined using an edited version of the program NIH Image, as described previously [12, 13, 18]. To be able to detect small differences in loading, blots were also probed with mouse anti beta-actin antibody (Sigma). Three independent experiments were evaluated.
Cell volume and viability
To determine whether DA can affect cell viability or volume, cells were seeded in duplicate in 24-well tissue culture plates and stimulated for 48 h with or without DA (10 μM). After that the cells were trypsinized and the average cell volume was examined using an electronic Coulter counter (CASY-TT, Schärfe System, Reutlingen, Germany).
To determine viability of cells in culture the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used. Cells were seeded in triplicate in 48-well tissue culture plates and stimulated for 48 h with DA (10 μM). The kit reagents were added directly to the cells in the well plate and luminescence of luciferase reaction, as a marker of cell viability, was measured with FLUOstar OPTIMA (BMG LABTECH GmbH, Offenburg/Germany).
Ovaries from four adult, cycling Sprague-Dawley rats (Charles River, Sulzfeld Germany)  were quickly removed and processed as described previously . The phases of the estrus cycles were not recorded. All methods unless specified, were previously described in detail [3, 9, 12, 13, 27, 28].
In situ hybridization (ISH)
The ISH procedures were performed as described previously [26, 28, 29]. Briefly, cryostat sections of ovaries were probed with a digoxigenin-uridine triphosphate labeled cRNA antisense or for control purposes, with sense probes. Templates for generation of riboprobes were partial RT-PCR derived cDNAs: rat D2 (291 bp partial cDNA subcloned in pGEM3Z; corresponding to position 1602–1893; see , Genbank accession NM_012547) and rat D1 (396 bp in pSP72, corresponding to 484–880; see , Genbank accession M35077). These templates were a gift from S. Ojeda to A. Mayerhofer. Riboprobes were transcribed with T7 RNA polymerase (Promega) or with SP6 RNA polymerase (Promega). Experiments were performed using sections of 4 individual rat ovaries.
Data are expressed as mean + SEM unless indicated otherwise in the text and graphs. Statistical significance of changes was determined using ANOVA and Newman-Keuls's post test (Ca2+ measurements) and by paired Student's t-test (comparison of cell volumes and ATP assay), performed with GraphPad Prism version 4.0a for Macintosh (GraphPad Software, San Diego California USA). Statistical significance was accepted for p < 0.05.
1. Evidence for D1,2,4,5 expression in human GCs
RT-PCR experiments performed with mRNA obtained from GCs on the 3rd or 4th day of culture yielded cDNAs of expected sizes (Fig. 1), which upon sequencing proved to be identical to the known human D1,2,4,5 sequences. Experiments using specific primers for D3 did not yield results. The presence of hCG in the medium did not alter levels of DA receptor D1,2,4,5 mRNAs, as judged from semiquantitative RT-PCR experiments when cyclophilin was used for normalization (Fig. 1).
Results of gene array experiments provided evidence for the presence of D1,2,5 (D4 was not represented on the array membrane; D3 was found to be not expressed; data not shown except for D2, see Fig. 3A).
By immunocytochemistry D1,2,4,5 receptors proteins were also demonstrated in virtually all GCs using specific D1,2,4,5 receptor antisera. D1,2,4,5 immunoreactivities were associated mainly with the cytoplasm of all GCs, and all controls performed were negative (Fig. 2). D2 immunoreactivity appeared to be strongest.
D2 receptor splice variant
For the human D2 we found evidence of the long splice variant, D2L, and also the short form was obtained using semi-nested second PCR steps, albeit the presence of this splice variant was inconsistent and appeared not to be associated with treatment or time in culture (Fig. 3B). Both splice variants were found also at the protein level by Western blot (Fig. 3C).
2. Evidence for D1,2 receptor gene expression in rat ovary
3. Elucidation of D2 receptor functionality in human GCs
Changes of intracellular Ca2+ levels in human GCs
Furthermore, the specificity of the DA action was shown by using the D2 blocker L-741,626 (1 nM), which prevented the Ca2+ increases (Fig. 5B; n = 7 experiments with 60–90 cells each). The response was not depending on the presence of extracellular Ca2+ in the medium, indicating release from intracellular sites (data not shown, n = 4 experiments with 20–50 cells each).
Interestingly, the numbers of cells responsive to DA by intracellular Ca2+ elevations were significantly (p < 0.05) higher when GCs were cultured in the presence of hCG, as compared to untreated cultures. The percentage of responding GCs to DA without hCG stimulation was 10.2% and 3.7% on the 3rd and on the 4th day of culture, respectively. After hCG exposure the percent of reacting cells was 24% and 21% on day 3 and 4, respectively, indicating a role of hCG in promoting D2 functionality (Fig. 5C).
4. Effects of DA on cell viability and volume of human GCs
Catecholamines, especially NE, have long been implicated in the control of ovarian function [1–9], but whether the catecholamine DA has a specific function within the ovary is not known. A prerequisite for such an action is the presence of functional receptors in the ovary. Our results show that most of the DA receptors are present in human GCs and that two members of each DA receptor family linked to different signaling pathways are co-expressed. Our results also show expression of two prototype DA receptor family members (D1/D2) in rat ovarian endocrine cells. This resembles the previously shown expression in horse ovary and extend our studies in human and monkey ovary .
For our studies we employed cultured human GCs, which stem from the preovulatory follicle and are undergoing luteinization. These like monkey granulosa and luteal cells, express D1 [12, 13] and as we found also D5. A previous study has shown that this receptor is linked to cAMP and DARPP-32 phosphorylation [12, 13]. D1 and D5 together are known also as the D1-like subfamily of DA receptors, which is linked to Gs and to a similar signaling pathway. It is possible that due to co-expression of D1/D5, which we have now observed, parts of the effects ascribed previously to D1 are actually due to (co)-activation of both receptors. The agonists/antagonist available in the concentrations we can use in our model, does not allow to distinguish between these subtypes or draw further conclusions [32–34].
The other D2-like subfamily of DA receptors consists of D2,3,4, of which two were found in human GCs, as well. D2 appeared to be strongly expressed, as judged from our results using a gene array, as well as immunocytochemistry and Western blotting. This subtype is also expressed in horse ovarian endocrine cells  and in rat follicles and corpus luteum (this study). We therefore chose to investigate this receptor subtype further.
That D2 mRNA can be alternatively spliced became evident in our study, as well. Evidence for constant expression of the long form splice variant (D2L) was obtained, while the short form (D2S) was found in an inconsistent manner and appeared not to be associated with time in culture. The antiserum used for both immunocytochemistry and Western blot detects both forms and either experiment indicated ubiquitous presence and high levels in all cultured GCs. Effects of hCG on mRNA and protein levels of this subtype or on possibly splice variants were also not obvious with the experimental approach chosen, and no changes were observed with regard to the expression of the other DA receptors in GCs, as well.
It is well established that action of DA on either splice variant of the D2 is linked to a phosphatidylinositol-linked mobilization of intracellular Ca2+ . Although all cells appeared to express the receptor protein, we found when we measured the Ca2+ response of individual cells to DA that only a percentage of the cultured cells showed indeed the expected changes. Furthermore, although we did not detect changes in overall levels of D2 in the presence of hCG in the culture medium, the percentage of responding GCs was significantly higher under these circumstances as compared to untreated cultures. The dependency on culture time or the presence of hCG indicate a relationship of the cellular differentiation state to D2 function and a role of the trophic hormone hCG/LH in promoting D2 functionality. Detailed insights e.g. at what level this may occur, are currently not possible and it remains, likewise, to be investigated whether possible transactivation of the D2, e.g. by EGF receptor  or other as yet unknown interactions may be involved.
In human the two splice variants, D2S and D2L, exhibit differences in the length of the third cytoplasmic loop involved in the coupling to G proteins [23, 24] and intracellular signaling [37, 38] other than phosphatidylinositol-linked mobilization of intracellular Ca2+. For example in neurons, D2L which is constantly present in human GCs, is in general also associated with inhibition of cAMP synthesis, stimulation of the MAP kinase pathway, activation of G protein coupled inwardly rectifying potassium channels (GIRKs), inhibition of Ca2+ channels, potentiation of arachidonic acid release and increased Na+/K+-ATPase activity [39, 40]. In the present report on this subject we were not able to address the full plethora of possible actions, but focused on effects of DA to mobilize Ca2+, which, by use of a specific D2 antagonist, were clearly shown. The Ca2+ mobilizing effect of DA was not dependent on the presence of extracellular Ca2+, i.e. it did most likely not involve opening of Ca2+ channels in the plasma membrane.
To summarize, human GCs possess four of the five known DA receptors, one of which exists in two possible splice variants and co-expression of these receptors is likely. Possible interactions of these DA receptors for example at the intracellular level (including DARPP-32) are to be assumed. Unfortunately the pharmacological tools available for the study of DA receptors in primary human GCs are limited [32–34], and antagonists/agonists interact often in a concentration-dependent manner with several receptors. Other approaches including siRNA are not readily possible for these primary cells. Clearly, the study of such interactions would be of great interest, for example with regard to DARPP-32, previously detected in human GCs and ovarian endocrine cells [12, 13, 18] or recently also in other endocrine tissue .
Therefore, a complete answer to the naive question about a specific role of DA in the ovary, which we posed, can not be given and may turn out to be much more complex than anticipated. Yet, a partial answer is provided by the results of the present study. By showing that four of the five known DA receptors are present in endocrine ovarian cells, they clearly indicate that DA is more than a precursor of NE (see Introduction). Ovarian endocrine cells are thus newly identified targets of ovarian DA and we assume based on our current results complex interactions between different DA receptor signaling cascades. Our study only provides first hints to an outcome of such actions, which implies a "trophic" role of DA for these cells. We found that treatment of cultured cells for up to 48 h with DA increased their size and viability, suggesting that DA may serve as a "differentiation factor". In brain, trophic actions of neurotransmitter are established [42, 43]. Insights into actions of yet another prototype neurotransmitter present in ovary, namely acetylcholine, which stimulates GCs proliferation and differentiation, supports the notions that neurotransmitters may act as local growth factors outside the brain [44, 45].
A role for ovarian DA is likely not restricted to GCs or endocrine cells, as other ovarian cells (e.g. oocytes,  or others) may have DA receptors or DA transporters, as well. It remains also to be investigated, whether ovarian microvasculature cells as reported in other tissues are affected by DA, which could be a profound modulator of VEGF actions and angiogenesis .
The presence of high ovarian DA levels on one side [1, 47] and of functional DA receptors on ovarian endocrine cells linked to different second messenger pathways, on the other side, imply as yet unknown ovarian signaling systems and specific roles of DA also in the human ovary. Furthermore, existence of the DA transporter and DBH in oocytes  or luteal cells , indicate actions of DA as a precursor for NE, within the ovary.
Taken together, these results may be of as yet unforeseeable relevance to human ovarian function. This assumption is based for example on the interaction of many drugs  with components of the DA and the NE system, including haloperidol, cocaine and others, which may be able to affect the ovary directly. It also remains to be studied, whether like in brain, DA and steroid hormone signaling may converge, a possibility shown for DA and progesterone . Finally, at least in animal studies, catecholamines (mainly NE) have been implicated in polycystic ovarian syndrome (PCOS; see ). Whether NE and specifically the catecholamine DA and ovarian DA receptors are involved in human PCOS, a common cause of infertility in women, remains to be studied. Our pilot studies indicate that in GCs from PCOS patients DA receptors are expressed (unpublished).
The present study shows that DA receptors are expressed by rat ovarian endocrine cells. Human GCs possess four of the five known DA receptors, one of which exists in two possible splice variants, and co-expression of these receptors is likely. Our results provide a basis for future studies addressing the role of these receptors for the ovary in health and disease.
We thank Annette Krieger, Christine Mayer, Romi Rämsch, Christine Roggors, Astrid Tiefenbacher and Barbara Zschiesche for technical assistance. The gift of D1 and D2 receptor cDNAs from Sergio Ojeda, ONPRC-OHSU, Beaverton, Oregon to AM is gratefully acknowledged. NL was supported by the Alexander von Humboldt Foundation through the resumption of a fellowship (Grant 1015945). This study was supported in major parts by DFG Ma1080/17-1 (to AM).
- Bodis J, Bognar Z, Hartmann G, Torok A, Csaba IF: Measurement of noradrenaline, dopamine and serotonin contents in follicular fluid of human graafian follicles after superovulation treatment. Gynecol Obstet Invest. 1992, 33 (3): 165-167.View ArticlePubMedGoogle Scholar
- Lara HE, Porcile A, Espinoza J, Romero C, Luza SM, Fuhrer J, Miranda C, Roblero L: Release of norepinephrine from human ovary: coupling to steroidogenic response. Endocrine. 2001, 15 (2): 187-192. 10.1385/ENDO:15:2:187.View ArticlePubMedGoogle Scholar
- Mayerhofer A, Smith GD, Danilchik M, Levine JE, Wolf DP, Dissen GA, Ojeda SR: Oocytes are a source of catecholamines in the primate ovary: evidence for a cell-cell regulatory loop. Proc Natl Acad Sci USA. 1998, 95 (18): 10990-10995. 10.1073/pnas.95.18.10990.PubMed CentralView ArticlePubMedGoogle Scholar
- Fohr KJ, Mayerhofer A, Sterzik K, Rudolf M, Rosenbusch B, Gratzl M: Concerted action of human chorionic gonadotropin and norepinephrine on intracellular-free calcium in human granulosa-lutein cells: evidence for the presence of a functional alpha-adrenergic receptor. J Clin Endocrinol Metab. 1993, 76 (2): 367-373. 10.1210/jc.76.2.367.PubMedGoogle Scholar
- Young FM, Menadue MF, Lavranos TC: Effects of the insecticide amitraz, an alpha2-adrenergic receptor agonist, on human luteinized granulosa cells. Hum Reprod. 2005, 20 (11): 3018-3025. 10.1093/humrep/dei194.View ArticlePubMedGoogle Scholar
- Kotwica J, Bogacki M, Rekawiecki R: Neural regulation of the bovine corpus luteum. Domest Anim Endocrinol. 2002, 23 (1–2): 299-308. 10.1016/S0739-7240(02)00165-0.View ArticlePubMedGoogle Scholar
- D'Albora H, Anesetti G, Lombide P, Dees WL, Ojeda SR: Intrinsic neurons in the mammalian ovary. Microsc Res Tech. 2002, 59 (6): 484-489. 10.1002/jemt.10231.View ArticlePubMedGoogle Scholar
- Dees WL, Hiney JK, Schultea TD, Mayerhofer A, Danilchik M, Dissen GA, Ojeda SR: The primate ovary contains a population of catecholaminergic neuron-like cells expressing nerve growth factor receptors. Endocrinology. 1995, 136 (12): 5760-5768. 10.1210/en.136.12.5760.PubMedGoogle Scholar
- Mayerhofer A, Dissen GA, Costa ME, Ojeda SR: A role for neurotransmitters in early follicular development: induction of functional follicle-stimulating hormone receptors in newly formed follicles of the rat ovary. Endocrinology. 1997, 138 (8): 3320-3329. 10.1210/en.138.8.3320.PubMedGoogle Scholar
- Oikawa M, Hsueh AJ: Beta-adrenergic agents stimulate tissue plasminogen activator activity and messenger ribonucleic acid levels in cultured rat granulosa cells. Endocrinology. 1989, 125 (5): 2550-2557.View ArticlePubMedGoogle Scholar
- Wiesak T, Przala J, Muszynska A, Hunter MG: Effect of catecholamines and FSH on progesterone secretion by pig granulosa cells. Endocrinol Exp. 1990, 24 (4): 449-456.PubMedGoogle Scholar
- Mayerhofer A, Fritz S, Grunert R, Sanders SL, Duffy DM, Ojeda SR, Stouffer RL: D1-Receptor, DARPP-32, and PP-1 in the primate corpus luteum and luteinized granulosa cells: evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin. J Clin Endocrinol Metab. 2000, 85 (12): 4750-4757. 10.1210/jc.85.12.4750.View ArticlePubMedGoogle Scholar
- Mayerhofer A, Hemmings HC, Snyder GL, Greengard P, Boddien S, Berg U, Brucker C: Functional dopamine-1 receptors and DARPP-32 are expressed in human ovary and granulosa luteal cells in vitro. J Clin Endocrinol Metab. 1999, 84 (1): 257-264. 10.1210/jc.84.1.257.PubMedGoogle Scholar
- King SS, Campbell AG, Dille EA, Roser JF, Murphy LL, Jones KL: Dopamine receptors in equine ovarian tissues. Domest Anim Endocrinol. 2005, 28 (4): 405-415. 10.1016/j.domaniend.2005.02.001.View ArticlePubMedGoogle Scholar
- Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, Cheramy A, O'Callaghan JP, Miller DB, Cole DG, Corbett R, Haile CN, Cooper DC, Onn SP, Grace AA, Ouimet CC, White FJ, Hyman SE, Surmeier DJ, Girault J, Nestler EJ, Greengard P: DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 1998, 281 (5378): 838-842. 10.1126/science.281.5378.838.View ArticlePubMedGoogle Scholar
- Greengard P: The neurobiology of slow synaptic transmission. Science. 2001, 294 (5544): 1024-1030. 10.1126/science.294.5544.1024.View ArticlePubMedGoogle Scholar
- Greengard P, Allen PB, Nairn AC: Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron. 1999, 23 (3): 435-447. 10.1016/S0896-6273(00)80798-9.View ArticlePubMedGoogle Scholar
- Mayerhofer A, Fritz S, Mani S, Rajendra Kumar T, Thalhammer A, Ingrassia P, Fienberg AA, Greengard P: Ovarian function and morphology after deletion of the DARPP-32 gene in mice. Exp Clin Endocrinol Diabetes. 2004, 112 (8): 451-457. 10.1055/s-2004-821205.View ArticlePubMedGoogle Scholar
- Fritz S, Kunz L, Dimitrijevic N, Grunert R, Heiss C, Mayerhofer A: Muscarinic receptors in human luteinized granulosa cells: activation blocks gap junctions and induces the transcription factor early growth response factor-1. J Clin Endocrinol Metab. 2002, 87 (3): 1362-1367. 10.1210/jc.87.3.1362.View ArticlePubMedGoogle Scholar
- Kunz L, Ramsch R, Krieger A, Young KA, Dissen GA, Stouffer RL, Ojeda SR, Mayerhofer A: Voltage-dependent K+ channel acts as sex steroid sensor in endocrine cells of the human ovary. J Cell Physiol. 2006, 206 (1): 167-174. 10.1002/jcp.20453.View ArticlePubMedGoogle Scholar
- Mayerhofer A, Föhr KJ, Sterzik K, Gratzl M: Carbachol increases intracellular free calcium concentrations in human granulosa-lutein cells. J Endocrinol. 1992, 135 (1): 153-159.View ArticlePubMedGoogle Scholar
- Frungieri MB, Albrecht M, Raemsch R, Mayerhofer A: The action of the mast cell product tryptase on cyclooxygenase-2 (COX2) and subsequent fibroblast proliferation involves activation of the extracellular signalregulated kinase isoforms 1 and 2 (erk1/2). Cell Signal. 2005, 17 (4): 525-533. 10.1016/j.cellsig.2004.09.017.View ArticlePubMedGoogle Scholar
- Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett DB, Bach A, Shivers BD, Seeburg PH: The dopamine D2 receptor: two molecular forms generated by alternative splicing. Embo J. 1989, 8 (13): 4025-4034.PubMed CentralPubMedGoogle Scholar
- Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L, Fischer JB, Burke-Howie KJ, Bunzow JR, Server AC, Civelli O: Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA. 1989, 86 (24): 9762-9766. 10.1073/pnas.86.24.9762.PubMed CentralView ArticlePubMedGoogle Scholar
- Albrecht M, Frungieri MB, Kunz L, Ramsch R, Meineke V, Kohn FM, Mayerhofer A: Divergent effects of the major mast cell products histamine, tryptase and TNF-alpha on human fibroblast behaviour. Cell Mol Life Sci. 2005, 62 (23): 2867-2876. 10.1007/s00018-005-5289-7.View ArticlePubMedGoogle Scholar
- Lazarov NE, Schmidt U, Wanner I, Pilgrim C: Mapping of D1 dopamine receptor mRNA by non-radioactive in situ hybridization. Histochem Cell Biol. 1998, 109 (3): 271-279. 10.1007/s004180050227.View ArticlePubMedGoogle Scholar
- Mayerhofer A, Dissen GA, Parrott JA, Hill DF, Mayerhofer D, Garfield RE, Costa ME, Skinner MK, Ojeda SR: Involvement of nerve growth factor in the ovulatory cascade: trkA receptor activation inhibits gap junctional communication between thecal cells. Endocrinology. 1996, 137 (12): 5662-5670. 10.1210/en.137.12.5662.PubMedGoogle Scholar
- Sommersberg B, Bulling A, Salzer U, Frohlich U, Garfield RE, Amsterdam A, Mayerhofer A: Gap junction communication and connexin 43 gene expression in a rat granulosa cell line: regulation by follicle-stimulating hormone. Biol Reprod. 2000, 63 (6): 1661-1668. 10.1095/biolreprod63.6.1661.View ArticlePubMedGoogle Scholar
- Lazarov N, Pilgrim C: Localization of D1 and D2 dopamine receptors in the rat mesencephalic trigeminal nucleus by immunocytochemistry and in situ hybridization. Neurosci Lett. 1997, 236 (2): 83-86. 10.1016/S0304-3940(97)00761-1.View ArticlePubMedGoogle Scholar
- Bunzow JR, Van Tol HH, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O: Cloning and expression of a rat D2 dopamine receptor cDNA. Nature. 1988, 336 (6201): 783-787. 10.1038/336783a0.View ArticlePubMedGoogle Scholar
- Monsma FJ, Mahan LC, McVittie LD, Gerfen CR, Sibley DR: Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation. Proc Natl Acad Sci USA. 1990, 87 (17): 6723-6727. 10.1073/pnas.87.17.6723.PubMed CentralView ArticlePubMedGoogle Scholar
- Kulagowski JJ, Broughton HB, Curtis NR, Mawer IM, Ridgill MP, Baker R, Emms F, Freedman SB, Marwood R, Patel S, Patel S, Ragan CI, Leeson PD: 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor. J Med Chem. 1996, 39 (10): 1941-1942. 10.1021/jm9600712.View ArticlePubMedGoogle Scholar
- Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, Bosc C, Rivet JM, Lacoste JM, Cordi A, Dekeyne A: S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000, 295 (3): 1206-1222.PubMedGoogle Scholar
- Pillai G, Brown NA, McAllister G, Milligan G, Seabrook GR: Human D2 and D4 dopamine receptors couple through betagamma G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively. Neuropharmacology. 1998, 37 (8): 983-987. 10.1016/S0028-3908(98)00092-6.View ArticlePubMedGoogle Scholar
- Liu YF, Civelli O, Grandy DK, Albert PR: Differential sensitivity of the short and long human dopamine D2 receptor subtypes to protein kinase C. J Neurochem. 1992, 59 (6): 2311-2317.View ArticlePubMedGoogle Scholar
- Wang C, Buck DC, Yang R, Macey TA, Neve KA: Dopamine D2 receptor stimulation of mitogen-activated protein kinases mediated by cell type-dependent transactivation of receptor tyrosine kinases. J Neurochem. 2005, 93 (4): 899-909. 10.1111/j.1471-4159.2005.03055.x.View ArticlePubMedGoogle Scholar
- Roberts DJ, Lin H, Strange PG: Mechanisms of agonist action at D2 dopamine receptors. Mol Pharmacol. 2004, 66 (6): 1573-1579. 10.1124/mol.104.004077.View ArticlePubMedGoogle Scholar
- Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E: Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000, 408 (6809): 199-203. 10.1038/35041572.View ArticlePubMedGoogle Scholar
- Banihashemi B, Albert PR: Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements. Mol Endocrinol. 2002, 16 (10): 2393-2404. 10.1210/me.2001-0220.View ArticlePubMedGoogle Scholar
- Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB: Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol. 2004, 66 (1): 97-105. 10.1124/mol.66.1.97.View ArticlePubMedGoogle Scholar
- Garcia-Jimenez C, Zaballos MA, Santisteban P: DARPP-32 (dopamine and 3',5'-cyclic adenosine monophosphate-regulated neuronal phosphoprotein) is essential for the maintenance of thyroid differentiation. Mol Endocrinol. 2005, 19 (12): 3060-3072. 10.1210/me.2005-0129.View ArticlePubMedGoogle Scholar
- Borta A, Hoglinger GU: Dopamine and adult neurogenesis. J Neurochem. 2007, 100 (3): 587-595. 10.1111/j.1471-4159.2006.04241.x.View ArticlePubMedGoogle Scholar
- Kotani S, Yamauchi T, Teramoto T, Ogura H: Pharmacological evidence of cholinergic involvement in adult hippocampal neurogenesis in rats. Neuroscience. 2006, 142 (2): 505-514. 10.1016/j.neuroscience.2006.06.035.View ArticlePubMedGoogle Scholar
- Mayerhofer A, Kunz L: A non-neuronal cholinergic system of the ovarian follicle. Ann Anat. 2005, 187 (5–6): 521-528.View ArticlePubMedGoogle Scholar
- Mayerhofer A, Kunz L, Krieger A, Proskocil B, Spindel E, Amsterdam A, Dissen GA, Ojeda SR, I W: FSH regulates acetycholine production by ovarian granulosa cells. Reprod Biol Endocrinol. 2006, 174 (4): 37-10.1186/1477-7827-4-37.View ArticleGoogle Scholar
- Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D: The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001, 7 (5): 569-574. 10.1038/87895.View ArticlePubMedGoogle Scholar
- Lara HE, Dorfman M, Venegas M, Luza SM, Luna SL, Mayerhofer A, Guimaraes MA, Rosa ESAA, Ramirez VD: Changes in sympathetic nerve activity of the mammalian ovary during a normal estrous cycle and in polycystic ovary syndrome: Studies on norepinephrine release. Microsc Res Tech. 2002, 59 (6): 495-502. 10.1002/jemt.10229.View ArticlePubMedGoogle Scholar
- Mani S: Signalling mechanisms in progesterone-neurotransmitter interactions. J Mol Endocrinol. 2003, 30 (2): 127-137. 10.1677/jme.0.0300127.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.